Janney Montgomery Scott LLC Has $3.33 Million Stake in United Therapeutics Co. (NASDAQ:UTHR)

Janney Montgomery Scott LLC boosted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 9.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,427 shares of the biotechnology company's stock after buying an additional 789 shares during the quarter. Janney Montgomery Scott LLC's holdings in United Therapeutics were worth $3,326,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. World Investment Advisors LLC acquired a new position in United Therapeutics in the 3rd quarter valued at about $139,206,000. FMR LLC boosted its holdings in shares of United Therapeutics by 41.1% during the third quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company's stock worth $386,168,000 after acquiring an additional 314,004 shares during the period. Assetmark Inc. grew its position in shares of United Therapeutics by 56.9% in the third quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company's stock valued at $150,492,000 after purchasing an additional 152,249 shares during the last quarter. Franklin Resources Inc. lifted its holdings in United Therapeutics by 97.7% during the 3rd quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company's stock worth $89,532,000 after purchasing an additional 123,929 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec lifted its holdings in United Therapeutics by 32.5% during the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 343,744 shares of the biotechnology company's stock worth $123,181,000 after purchasing an additional 84,369 shares during the last quarter. Institutional investors own 94.08% of the company's stock.

Analyst Upgrades and Downgrades

UTHR has been the topic of several recent research reports. TD Cowen increased their price objective on United Therapeutics from $350.00 to $400.00 and gave the stock a "buy" rating in a research report on Monday, October 21st. StockNews.com raised shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Thursday, January 16th. The Goldman Sachs Group boosted their price objective on shares of United Therapeutics from $243.00 to $302.00 and gave the company a "neutral" rating in a report on Friday, November 1st. LADENBURG THALM/SH SH raised their target price on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. Finally, UBS Group boosted their price target on United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $378.36.

United Therapeutics Trading Down 0.3 %

NASDAQ UTHR traded down $1.15 during trading on Tuesday, hitting $353.43. 312,063 shares of the company's stock were exchanged, compared to its average volume of 301,121. The stock's 50 day moving average price is $364.28 and its two-hundred day moving average price is $357.68. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $417.82. The company has a market cap of $15.78 billion, a PE ratio of 15.52, a P/E/G ratio of 0.92 and a beta of 0.57.

Insider Activity at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 15,000 shares of the stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $407.32, for a total value of $6,109,800.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Nilda Mesa sold 255 shares of the business's stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $355.77, for a total value of $90,721.35. Following the sale, the director now owns 5,528 shares in the company, valued at approximately $1,966,696.56. This trade represents a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 143,838 shares of company stock valued at $53,981,956 in the last quarter. Insiders own 11.90% of the company's stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.